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Abstract
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several regions. This paper proposes recommendations 
for probiotics in pediatric gastrointestinal diseases 
in the Asia-Pacific region. Epidemiology and clinical 
patterns of intestinal diseases in Asia-Pacific countries 
were discussed. Evidence-based recommendations 
and randomized controlled trials in the region were 
revised. Cultural aspects, health management issues 
and economic factors were also considered. Final 
recommendations were approved by applying the Likert 
scale and rated using the GRADE system. Saccharomyces 
boulardii  CNCM I-745 (Sb) and Lactobacillus rhamnosus 
GG (LGG ) were strongly recommended as adjunct 
treatment to oral rehydration therapy for gastroenteritis. 
Lactobacillus reuteri  could also be considered. Probiotics 
may be considered for prevention of (with the indicated 
strains): antibiotic-associated diarrhea (LGG or Sb); 
Clostridium difficile -induced diarrhea (Sb); nosocomial 
diarrhea (LGG); infantile colic (L reuteri ) and as adjunct 
treatment of Helicobacter pylori  (Sb and others). Specific 
probiotics with a history of safe use in preterm and term 
infants may be considered in infants for prevention of 
necrotizing enterocolitis. There is insufficient evidence 
for recommendations in other conditions. Despite a 
diversity of epidemiological, socioeconomical and health 
system conditions, similar recommendations apply well 
to Asia pacific countries. These need to be validated with 
local randomized-controlled trials.
Key words: Lactobacillus rhamnosus ; Gastroenteritis; 
Guidelines; Probiotics; Children; Recommendations; 
Asia-Pacific; Saccharomyces  boulardii
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This paper includes recommendations based 
on guidelines and local data for use of probiotics strains 
in the prevention or treatment of intestinal diseases in 
children of Asia-Pacific region. Notwithstanding major 
differences in health management and local conditions 
between countries, recommendations for children living 
in various countries of Asia-Pacific region are similar. 
Saccharomyces boulardii  and Lactobacillus rhamnosus 
GG may be used in gastroenteritis, nosocomial infections, 
antibiotic-associated diarrhea. Selected strains may 
have a place in infantile colic, Helicobacter pylori  
treatment, and necrotizing enterocolitis. This document 
provides a helpful guidance to use probiotics in children 
based on local data and considerations. 
Cameron D, Hock QS, Kadim M, Mohan N, Ryoo E, Sandhu 
B, Yamashiro Y, Jie C, Hoekstra H, Guarino A. Probiotics 
for gastrointestinal disorders: Proposed recommendations for 
children of the Asia-Pacific region. World J Gastroenterol 2017; 
23(45): 7952-7964  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i45/7952.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i45.7952
INTRODUCTION
Gastrointestinal illnesses are a major cause of morbidity 
and mortality in children in developing countries[1], with 
diarrheal diseases being one of the top five causes of 
death in children younger than five years[2]. Worldwide, 
the most important enteric pathogen is rotavirus[2,3]; 
other major pathogens include Escherichia coli, Vibrio 
cholera, and Shigella, Campylobacter, Salmonella, and 
Cryptosporidium species[4,5].
In the Asia-Pacific region, the distribution of enteric 
pathogens shows marked regional variations, with 
differences largely corresponding to the predominant 
socioeconomic status of each region[2]. The Asia-
Pacific region, comprising more than half of the world’
s total population, is an area that is particularly diverse 
politically, economically, and culturally, including some 
of the world’s least and some of the most developed 
nations[6]. While many in the Asia-Pacific region struggle 
to meet the most basic survival needs, a substantial 
proportion of the population in this region is moving 
towards Western diets and unhealthy lifestyles[6]. 
The human gut microbiota is emerging as a major 
determinant of intestinal and non-intestinal diseases. 
The human gut is home to a diverse collection of 
microbes, collectively termed gut microbiota, the 
disruption of which is associated with gastrointestinal 
diseases[7]. Moreover, it is becoming clear that 
geographic variations in the composition of the gut 
microbiota are likely to affect the risk of developing 
specific diseases[8]. These geographic variations may 
be due to a number of factors, including diet, culture, 
and genetics[9]. The relationship between disruption 
of gut microbiota and the risk of disease development 
and symptom severity suggests that the use of 
certain probiotics strains may prevent or reduce the 
progression of damage caused by some gastrointestinal 
illnesses.
Probiotics are live microorganisms that when 
administered in adequate amounts confer a health 
benefit[10]. While there exists a substantial body of 
literature regarding the use of probiotics in numerous 
human diseases, the quality of evidence for their 
use is variable, with evidence lacking for many 
indications. A number of organizations and institutions 
have reviewed the currently available evidence and 
developed recommendations for probiotics use at 
national or international level[10-14]. In order to propose 
recommendations for the use of probiotics in children 
of the Asia-Pacific region, a group of experts met to 
review and discuss existing recommendations, as well 
as the relevant available data regarding the proposed 
recommendations for Asia-Pacific.
METHODS
With the objective of formulating recommendations for 
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use of probiotics in pediatric gastrointestinal disorders in 
the Asia-Pacific region, a working group of international 
experts in adult and pediatric gastroenterology 
from Asia-Pacific countries (Australia, China, India, 
Indonesia, Japan, South Korea, and Singapore), as well 
as from several countries outside the region (United 
States, Uruguay, United Kingdom, The Netherlands, 
and Italy) met to discuss the indication for use of 
probiotics based on local epidemiological conditions. 
Workshops on the gastrointestinal epidemiology of the 
represented countries and the use of probiotics in both 
adults and children were held. This article describes 
the proposed recommendations for use of probiotics in 
intestinal diseases in children in the Asia-Pacific region. 
The main considerations in the development of these 
consensus recommendations were the epidemiology 
and etiology of gastrointestinal diseases in the Asia-
Pacific region, and the evidence from the region and 
internationally to support the use of probiotics for 
different pediatric gastrointestinal conditions.
The method used to develop the recommenda-
tions consisted of multiple steps (Figure 1). Initially, 
target diseases and their impact were defined, and 
the definitions and outcomes for each disease were 
agreed upon. Published data and available evidence-
based recommendations and guidelines from the Asia-
Pacific region and from other organizations, such as 
the World Gastroenterology Organization (WGO), 
European Society for Pediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN), North American 
Society for Pediatric Gastroenterology, Hepatology and 
Nutrition (NASPGHAN), Latin American Society for 
Pediatric Gastroenterology and Nutrition (LASPGAN), 
were studied and discussed. Subsequently, the local 
epidemiological and clinical features of the main 
intestinal diseases commonly seen in the Asia-Pacific 
region were discussed to determine their impact on the 
recommendations. Randomized-controlled trials (RCTs) 
on the effect of probiotics on gastrointestinal diseases, 
which were conducted in the Asia-Pacific region, written 
in English and published in peer review journals after 
2005 were also evaluated. The discussion included 
epidemiological data, local practices and traditions, 
availability of probiotics and other drugs , standards of 
care, perception of specific disease risk and the need 
for prevention, economic considerations, and other 
health management issues (e.g., private vs public 
medicine).
The final recommendations were based on these 
steps using the GRADE system[15] and the strength of 
each individual recommendation was rated as weak or 
strong.
An overview of the steps used for designing the 
recommendations for acute gastroenteritis is shown in 
Figure 2.
Once the recommendations were designed, the 
participants from the Asia-Pacific region were asked to 
provide a consensus on the proposed recommendations 
using the Likert scale[16]. The recommendations were 
further revised based on the feedback received after 
circulating the proposed recommendations to countries 
in the Asia-Pacific region until final consensus was 
achieved as judged by agreement by all participants 
with grade 4 or 5 in the Likert scale (corresponding 
to “agree” and “strongly agree”, respectively). The 
final steps will be the validation of recommendations 
through field trials to evaluate their applicability and 
efficacy using previously tested methodology[17]. 
THE HUMAN GUT MICROBIOME
The human gut microbiota includes a vastly diverse 
community of microorganisms that, together with the 
collection of all of the genomic elements of the specific 
microbiota, comprises the human gut microbiome[18]. 
With the development of increasingly advanced 
molecular methods in recent years, such as high-
throughput sequencing, our interest in and unders-
tanding of the human gut microbiome have significantly 
increased.
It has become apparent that the microbiome is 
influenced by numerous factors, including age, geography, 
diet, lifestyle, disease, and antibiotic exposure[9,19,20]. 
Notably, while it has long been known that a course 
of antibiotics impacts the gut microbiome in the short 
term, there is also evidence to suggest that exposure 
to antibiotics may have a long-term impact on the 
human intestinal microbiota that persists for as long as 
2 years after treatment[19]. 
While much of the function of the human gut micro-
biome remains to be fully elucidated, we do know that 
the microbiota plays an important role in maintaining 
health[20]. The role of microbiota includes the prevention 
of colonization by pathogens and development and 
activation of the immune system, as well as an 
important role in stability of metabolism[20]. When the 
gut microbiota is functioning as expected in a healthy 
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Agree upon definitions
Agree upon outcomes
Look for local evidence Revise setting and population
Build draft recommendations
Agree upon recommendations
Validate recommendations at local level
Figure 1  Steps for designing the recommendations for the use of 
probiotics in pediatric population in the Asia-Pacific region.
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as well as nutritional factors[26]. Moreover, effective 
interventions are not provided equitably across all 
communities[26].
Infectious diarrhea is a major concern in the Asia-
Pacific region. Worldwide, the most frequent causative 
pathogen for infectious diarrhea is rotavirus, responsible 
for approximately 40% of all hospital admissions for 
diarrhea of infants and young children[5]. A specific 
feature of certain Asian countries is the circulation of 
V. cholerae that may be multidrug-resistant and cause 
severe diarrhea[27]. Other major pathogens include E. 
coli, Shigella, Campylobacter, and Salmonella species, 
as well as the protozoan pathogen Cryptosporidium 
that is an important enteric pathogen in children of 
some Asian Countries[5]. The pathogens responsible 
for diarrheal deaths vary between regions[2]. In a 
recent study, 5304 stool samples from Africa and Asia 
(Bangladesh, India and Pakistan) were analyzed and 
results show that approximately 80% of gastroenteritis 
in children are caused by six pathogens (Shigella, 
Rotavirus, Adenovirus 40/41, Heat-stable enterotoxin-
producing E coli or ST-ETEC, Cryptosporidium and 
Campylobacter)[28]. Interestingly, Clostridium difficile 
(C. difficile) was an important pathogen in high-income 
countries, while Shigella and Aeromonas infections 
occurred at a higher frequency in areas with poor 
sanitation[2]. 
In addition to infectious diarrhea, there are several 
other diseases of importance in the Asia-Pacific region, 
such as AAD (including C. difficile-associated diarrhea), 
H. pylori infection, irritable bowel syndrome (IBS), and 
IBD. The incidence of the latter condition is sharply 
increasing in some locations; however, the relative 
prevalence of individual diseases differs from region 
to region, as well as across countries within the Asia-
Pacific region[29-31]. For example, H. pylori is found in 
half of the world’s population, although its prevalence 
and clinical manifestations vary markedly in relation 
to numerous factors, including geography, age and 
socioeconomic factors, with prevalence much higher in 
developing countries[32]. 
In addition to epidemiological factors, the organi-
zational and economic features that differ throug-
hout Asia-Pacific countries play a major role in the 
implementation of treatment guidelines[33]. 
PROBIOTICS
Probiotics are live microorganisms that when admi-
nistered in adequate amounts confer a health benefit[10]. 
A substantial body of evidence suggests that the clinical 
effects of probiotics in humans include prevention 
and treatment of diarrhea, immunomodulation, and 
modulation of intestinal flora[14]. The short-term effects 
of probiotics, such as those seen in patients with 
acute diarrhea, are due to the direct effect of specific 
probiotic strains on pathogens present in the human 
gut, whereas many of their long-term effects are the 
person, it is in balance or eubiosis. In contrast, in a 
number of diseases the gut microbiota exists in a state 
of dysbiosis[20].
The composition of microbiota is altered in cer-
tain disease states, including enteric infections, He­
licobacter pylori (H. pylori) infection and antibiotic-
associated diarrhea (AAD)[20]. Furthermore, aberrations 
in microbial configuration are often associated with 
specific chronic diseases, producing a “microbial 
signature” of the specific disease[21,22], although the 
cause-effect relationship between microbial change 
and disease is not clear. There appears to be a link 
between dysbiosis and disease, including inflammatory 
bowel diseases (IBD), celiac disease, diabetes, cancer, 
obesity, and cystic fibrosis[22-24].
EPIDEMIOLOGY OF GASTROINTESTINAL 
DISEASES IN THE ASIA-PACIFIC REGION
While patterns of diseases worldwide are constan-
tly changing, diarrhea remains a leading cause of 
mortality among children younger than five years[25]. 
The burden of this disease is not shared equally, but 
is disproportionately borne by children in low income 
countries, largely due to water and sanitation issues, 
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   Is the tested probiotic available in the market?
   Is there any other intervention currently used?
   Are probiotics a priority for the treatment of acute 
   gastroenteritis in your country?
Figure 2  Steps for designing the recommendations for acute gastroenteritis.
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result of an interaction between selected strains and 
the host immune response or the reconstitution of the 
disrupted intestinal barrier[34].
In general, the effects of probiotics are strain-, 
disease- and age-specific[14]. Administration of multi-
ple strains is not necessarily better or worse than a 
single strain, rather use of specific probiotic strains 
or preparations should rely on clinical data from at 
least one well-designed trial of a well-characterized 
probiotic preparation[34]. Several meta-analyses 
combining data from studies of different probiotic 
strains in different patient populations produced results 
that were largely inconclusive[35-39]. Furthermore, the 
definitions and outcome parameters used in different 
studies are often heterogeneous, which may limit 
the interpretation of data available. Thus, although 
meta-analyses can be used to establish the effects of 
probiotics, they may underestimate the benefits of 
selected strains or amplify the efficacy of less effective 
strains if not performed appropriately. In addition, 
there is a high level of heterogeneity among microbial 
preparations, as well as a lack of quality control for 
commercially-available products. On the other hand, 
for selected strains and pathologies, there are a high 
number of well-conducted RCTs with compelling 
proof of efficacy[40,41]. Finally, it is recognized that the 
dose of probiotics used in children may be important, 
particularly when evaluating their efficacy in growing 
children, although currently data are limited.
Safety and regulatory issues are also important 
considerations and may act as barrier against the use 
of probiotics. Overall, the available evidence suggests 
that probiotics are generally safe[34], with long-term 
studies demonstrating the safety of L. rhamnosus GG 
in very low birth weight preterm infants[42] and probiotic 
strains (L. rhamnosus GG, Bifidobacterium lactis 
Bb­12, Lactobacillus paracasei ST11, and B. longum 
BL999) administered during the perinatal period[43]. 
However, it should be noted that there are a number 
of potential risks associated with the use of probiotics, 
and there is limited data specifically addressing the 
safety of these agents[14,44]. To date, known risks 
associated with use of probiotics are largely confined 
to specific patient populations, including premature 
infants, immunocompromised individuals and critically 
ill patients[14,44]. A study on probiotics from dietary 
supplements reported the presence of antibiotic 
resistance in selected strains, although further studies 
exploring the mechanism by which this resistance is 
conferred are warranted[45]. 
The current regulatory scenario of probiotics pro-
vides a scattered picture, with probiotics classified 
as food additives or as drugs in different countries. 
For instance, in Indonesia, probiotics are classified as 
supplements, and some strains (including Sacchar­
omyces boulardii) are not available due to these 
regulations. A recent paper provides an overview of 
how probiotics are categorized in the world[46].
Furthermore, L. rhamnosus GG is not commonly 
used in Japan, where L. casei Shirota-fermented 
milk is widely available. The implementation of the 
recommendations for the use of probiotics is likely to 
be influenced by those factors.
Based on these findings, and keeping in mind that 
the main basis for prescribing probiotics is the data 
on clinical efficacy, the experts produced the following 
recommendations for intestinal diseases of children in 
the Asia Pacific region. The proposed recommendations 
could be modified according to the country-specific 
level of evidence.
PROPOSED RECOMMENDATIONS FOR 
PROBIOTICS
Acute gastroenteritis
Infectious diarrhea is the best established indication 
for probiotics administration in childhood. A position 
paper by ESPGHAN for the use of probiotics in the 
management of acute gastroenteritis in infants and 
children proposed that since the effects of probiotic 
are strain-specific, the recommendations for the use 
of an individual probiotic should be made based on 
the efficacy and safety of the probiotic from well-
established RCTs and that the efficacy and safety of a 
particular strain should not be extrapolated to another 
strain[47]. Furthermore, a probiotic preparation should 
be selected from a manufacturer who has adequate 
quality control, and the lack of current evidence on the 
use of a particular probiotic does not mean that it will 
prove to be ineffective in future studies[47]. According 
to the ESPGHAN/European Society of Pediatric 
Infectious Diseases guidelines for the management of 
acute gastroenteritis in children in Europe, probiotics 
provide an “active therapy” to reduce the duration 
and severity of symptoms. The guidelines strongly 
recommend the use of probiotics as an adjunct to 
rehydration therapy. Based on large number of high 
quality RCTs, L. rhamnosus GG and S. boulardii were 
recommended (Table 1)[40]. L. reuteri DSM 17938 was 
also included in the list of effective strains, albeit with 
a weak recommendation. Few RCTs are available for 
other strains or combinations of strains in children 
with acute gastroenteritis. Some RCTs were conducted 
in Asian countries with variable results[48]. A double-
blind randomized trial found probiotics to be ineffective 
in acute diarrhea in Indonesian children[49]. However, 
because data are limited or have methodological 
issues, many strains were not considered for inclusion 
in the present recommendations.
A position similar to ESPGHAN was taken in the 
United States, where the indications for probiotics 
were discussed in the 4th Triennial Yale/Harvard 
Workshop on Probiotic Recommendations[12]. Similar 
recommendations were published in South America[50], 
and the Latin-American consensus guidelines on the 
use of probiotics in pediatric gastroenterology suggest 
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that L. rhamnosus GG, S. boulardii, and (with a weak 
recommendation) L. reuteri are effective against 
diarrhea and should be introduced at the onset of 
gastroenteritis[50]. The WGO also published a position 
paper on the indications for probiotics in adults and 
children[51]. The recommendations made for the use of 
probiotics in acute gastroenteritis, according to main 
geographic region and indication, are summarized in 
Table 1.
Other national and international guidelines provide 
recommendations for the management of gastroenteritis. 
A group of experts examined 15 guidelines from all over 
the world for management of acute gastroenteritis in 
children, of which nine guidelines recommended the use 
of probiotic strains for treatment of gastroenteritis[52]. 
In most guidelines, the recommended strains included 
L. rhamnosus GG and S. boulardii. Notably, selected 
countries in the Asia-Pacific region have adopted 
guidelines recommending effective use of probiotics for 
management of gastroenteritis.
A study conducted in India explored deviations from 
the WHO guidelines in the management of diarrhea in 
children[53]. The most common deviation from the WHO 
guidelines was in relation to the addition of probiotics. 
This study also found that the use of probiotics reduced 
the duration of symptoms[53]. 
The panel of experts also discussed the etiolog-
ical patterns, features, and the risk factors for acute 
gastroenteritis. It was observed that the epidemiology 
of enteric pathogens, the features of disease, the 
incidence of risk factors (mainly childhood malnutrition) 
and the organization of health care provide a broad 
and variable picture in the Asia-Pacific region. While 
the efficacy of probiotics is not strictly related to the 
etiology, it is likely that the highest efficacy is exerted in 
viral rather than bacterial gastroenteritis. Overall, most 
guidelines recommend the same probiotic strains for 
active therapy of gastroenteritis, based on consistent 
data showing similar efficacy of recommended 
strains in various settings and conditions. However, 
the progressive introduction of immunization against 
rotavirus may alter the etiologic and epidemiologic 
pattern of gastroenteritis, as already reported in 
many countries including countries in the Asia-Pacific 
region[54]. Norovirus is an emerging etiologic agent, 
and data regarding the efficacy of L. rhamnosus GG, 
S. boulardii, and other probiotics against this virus are 
limited. It was also noted that there are no clear data 
about the efficacy of probiotics in patients with cholera, 
although there is weak evidence that probiotics may 
have some preventive effect[55]. Furthermore, there 
is little evidence regarding the efficacy and safety of 
probiotics in malnourished children. Since the incidence 
of malnutrition is high in several countries with poor 
living conditions in the Asia-Pacific region, additional 
studies are needed to specifically address the use of 
probiotics in gastroenteritis in undernourished pediatric 
populations living in these regions.
After discussing the current evidence and issues 
regarding the use of probiotics, the expert panel 
agreed upon recommending L. rhamnosus GG and 
S. boulardii CNCM I-745 for management of gastr-
oenteritis in the Asia-Pacific region as an adjunct to 
rehydration. Inclusion of L. reuteri DSM 17938 may 
also be used although the quality of evidence for the 
latter strain is weak[39].
Antibiotic-associated diarrhea including C. difficile-
induced diarrhea
AAD is a major global issue, with children being at a 
higher risk than adults. AAD has become an important 
problem due to the general overuse of antibiotics in 
children in most Asia-Pacific countries[29,56]. C. difficile 
is a major causative agent for AAD, both in terms of 
Table 1  Recommendations for use of probiotics in childhood intestinal diseases by geographic region
Diseases Europe[14,40] United States[36] Latin America[50] World[51]
Acute gastroenteritis T L. rhamnosus GG, S. 
boulardii, L reuteri
L. rhamnosus GG, S. 
boulardii
L. rhamnosus GG, S. boulardii, L. 
reuteri
S. boulardii, L. rhamnosus GG, Indian 
Dahi
AAD P L. rhamnosus GG, S. 
boulardii
L. rhamnosus GG, S. 
boulardii
L. rhamnosus GG, S. boulardii S. boulardii; L. rhamnosus GG, , B. lactis 
Bb12 + S. thermophilus, L. rhamnosus 
strains E/N, Oxy and Pen
CDAD P S. boulardii
Nosocomial diarrhea P L. rhamnosus GG L. rhamnosus GG L. rhamnosus GG, B. lactis Bb12, S. 
thermophilus, B. bifidum
L. rhamnosus GG, B. lactis Bb12 + S. 
Thermophilus
Traveler’s diarrhea P S. boulardii
Functional intestinal 
disorders (IBS)
T Insufficient evidence L. rhamnosus GG, VSL#3 L. rhamnosus GG, L. reuteri DSM 17938
Infant colic T L. reuteri DSM 17938 L. reuteri DSM 17938 L. reuteri DSM 17938
IBD (CD, UC, 
pouchitis)
T E. coli Nissle 1917, 
VSL#31
VSL#31 VSL#32
Helicobacter pylori 
infection
T Not recommended L. casei DN-114 001
1Available evidence supports use in UC but not CD or pouchitis; 2For mildly active UC. T: Treatment; P: Prevention; AAD: Antibiotic-associated diarrhea; 
CDAD: Clostridium difficile-associated diarrhea; CD: Crohn’s disease; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome; UC: Ulcerative 
colitis; VSL#3: Proprietary mixture of eight probiotic strains.
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frequency and severity[57]. Available data suggest that 
probiotics, including L. rhamnosus GG and S. boulardii 
CNCM I­745, are effective in the prevention of AAD[58] 
and C. difficile infections in pediatric populations[57,58]. 
The ESPGHAN working group recommendations on 
the use of probiotics for prevention of AAD in children 
suggest that physicians should evaluate the risk factors 
for the occurrence of AAD or C. difficile-associated 
diarrhea, such as the class of antibiotics, duration of 
antibiotic treatment, need for hospitalization, age, 
comorbidities, and previous episodes of AAD or C. 
difficile-associated diarrhea, before making decisions 
on the use of probiotics for the prevention of AAD 
in children[41]. The working group provides strong 
recommendations for the use of L. rhamnosus GG 
or S. boulardii CNCM I-745 for AAD prevention and 
a weak recommendation for the use of S. boulardii 
CNCM I-745 for the prevention of C. difficile-associated 
AAD[41]. 
Direct clinical data are available from the Asian 
region. A study conducted in China evaluated the 
efficacy of S. boulardii for the prevention and treatment 
of diarrhea in children receiving intravenous antibiotics 
for lower respiratory infections[59]. Administration 
of S. boulardii was associated with a significantly 
reduced risk of developing AAD (RR = 0.22, 95%CI: 
0.1-0.5) and a reduction in the duration and severity 
of diarrhea[59]. But, in a recent Korean study, the use 
of probiotics was not associated with any significant 
differences with regard to prevention of C. difficile 
infection[60].
The expert group supports probiotic administration 
for the prevention of AAD. Either L. rhamnosus GG 
or S. boulardii CNCM I-745 should be administered 
as treatment, whereas based on available clinical 
evidence, the best option for prevention of C. difficile-
associated diarrhea in children is administration of S. 
boulardii CNCM I-745.
Nosocomial diarrhea
Nosocomial diarrhea is an important issue in the 
Asia-Pacific region, mainly due to the high frequency 
of rotavirus infection[61]. Any coexisting respiratory 
infection can amplify the impact of nosocomial diarrhea, 
resulting in exacerbation of the clinical condition. 
Although evidence regarding the efficacy of probiotics 
in the prevention of nosocomial infections remains 
unclear[62], available data show that L. rhamnosus 
GG may be effective in the treatment of intestinal 
nosocomial infections in children[63,64].
Based on available data, the expert group recom-
mends that administration of L. rhamnosus GG can be 
considered in hospitalized children for the prevention 
of intestinal infections.
Traveler’s diarrhea
Traveler’s diarrhea was also discussed during the 
meeting and it was observed that there is no strong 
evidence of an increased risk of diarrhea among children 
who live within the Asia-Pacific region and travel 
elsewhere. In addition, data on the efficacy of probiotics 
in preventing traveler’s diarrhea are insufficient to 
provide recommendations[65]. Nevertheless, the Latin-
American consensus guidelines recommend S. boulardii 
for the prevention of traveler’s diarrhea in children 
based on RCT evidence[50]. L. rhamnosus GG and L. 
acidophilus appear to be ineffective, while there is 
some limited evidence that S. boulardii administration 
is associated with a significant reduction in diarrhea 
incidence[50].
The expert group does not recommend the use of 
probiotics for the prevention of traveler’s diarrhea in 
children in the Asia-Pacific region.
Functional intestinal disorders
Early studies on the epidemiology of functional inte-
stinal disorders in the Asia-Pacific region suggest 
that these conditions are common[66]. According to 
the WGO global guidelines, several studies have 
demonstrated significant therapeutic gains with pro-
biotics over placebo in the symptomatic treatment of 
IBS, although most trials were performed in adults[34]. 
A reduction in abdominal bloating and flatulence as 
a result of probiotic treatment is a consistent finding 
in published studies, and some strains (including B. 
infantis 35624) may also reduce abdominal pain and 
provide systemic relief. However, there is only limited 
evidence on the efficacy of probiotics in the treatment 
of functional intestinal disorders in children[37,67,68]. 
Based on available data, there is insufficient evi-
dence to recommend probiotics in the treatment of 
functional intestinal disorders.
Infant colic
Colic is a disturbing condition in infants that frequently 
requires medical consultation and therapy. Dysbiosis 
may affect gut motor functions and gas production, 
resulting in colicky abdominal pain in infants. Data 
from RCTs indicate that probiotics may be effective 
for the treatment of infant colic, with L. reuteri being 
identified as the most effective strain[69,70]. 
If infant colic is perceived as a problem in need of 
active intervention, administration of effective probiotics, 
particularly L. reuteri DSM 17938, may be considered.
Inflammatory bowel diseases
As shown in Table 1, the WGO global guidelines address 
the role of probiotics in IBD, particularly ulcerative 
colitis and Crohn’s disease (including pouchitis)[34]. 
Regarding pouchitis, there is good evidence for the 
efficacy of VSL#3 (a mixture of eight probiotic strains 
including Lactobacilli, Bifidobacteria, and Streptococcal 
species) in preventing the initial episode and further 
relapses of pouchitis after induction of remission 
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with antibiotics. Overall, the guidelines conclude that 
probiotics are recommended for patients with pouchitis 
of mild activity or as maintenance therapy for those in 
remission. For ulcerative colitis, the guidelines suggest 
that E. coli Nissle may be as effective as mesalazine 
in maintaining remission of ulcerative colitis, and that 
VSL#3 has efficacy in the induction and maintenance 
of remission of mild to moderate ulcerative colitis. For 
Crohn’s disease, the guidelines note that probiotics are 
less effective, as reported in a Cochrane systematic 
review, which concluded that there is no evidence 
to indicate a beneficial effect of probiotics in the 
maintenance of remission in Crohn’s disease[34,71]. 
Other guidelines are less open to consider probiotics 
as a general intervention for intestinal inflammatory 
conditions (Table 1).
The expert panel concluded that overall, there 
appears to be limited evidence to support the use 
of probiotics for the treatment of IBD in children. 
In pouchitis, VSL#3 may be considered based on 
evaluation of individual cases.
H. pylori infection 
H. pylori infection is a major concern in most Asian 
countries[72-74]. In addition the rate of H. pylori anti-
biotic resistance is high in Asian population[75]. A 
review on the use of probiotics in the treatment of H. 
pylori infections in children indicates that probiotics 
may be beneficial in improving the eradication rate 
of H. pylori infections and a meta-analysis of RCTs 
provided further support. However, these effects are 
strain-specific and additional long-term studies are 
needed to establish the efficacy of different strains 
and doses of probiotics in the management of these 
infections[76]. A systematic review and meta-analysis of 
11 RCTs, including a total of 2200 participants (among 
whom 330 were children), found an increase in H. 
pylori eradication rate with the addition of S. boulardii 
to antibiotic treatment[38]. Eighty percent of patients in 
the S. boulardii group achieved eradication of H. pylori 
compared with 71% of patients in the control group 
(RR = 1.11, 95%CI: 1.06-1.17). Moreover, compared 
with controls, S. boulardii reduced the overall risk of 
H. pylori therapy-related diarrhea. However, since the 
number of children included in the studies was limited, 
additional studies in children are warranted.
WGO global guidelines report that several Lacto-
bacilli strains appear to reduce the side effects of 
antibiotic therapies for H. pylori and improve patient 
compliance[34]. However, while there is evidence to 
suggest that supplementation of H. pylori antibiotic 
treatment regimens with certain probiotics may 
help eradication, the guidelines state that “there is 
currently insufficient evidence to support the concept 
that a probiotic alone, without concomitant antibiotic 
therapy, would be effective”[34]. An international 
consensus document, developed following the 5th 
Maastricht/Florence Consensus Conference in 2016, 
concluded that certain probiotics (such as Lactobacilli 
and S. boulardii) show favorable results as adjuvant 
treatment in H. pylori infection for reducing side 
effects, with a positive effect on patient compliance 
with the extensive antibiotic regime[77]. In a recent 
meta-analysis the efficacy of probiotics administration 
in improving eradication rates and in reducing side 
effects of therapy was confirmed. In subgroup analysis 
there was no difference between Asia and Europe, 
but probiotics were more effective in children than in 
adults. However several strains, including S. boulardii, 
were effective and may be considered in adjunct 
eradication therapy[78]. 
Based on available data, the Asia-Pacific expert 
panel suggests that probiotic strains with evidence 
of efficacy, such as S. boulardii CNCM I-745, may be 
considered for the prevention of side effects of antibiotic 
therapy for H. pylori and for improving eradication rates 
in children.
Necrotizing enterocolitis
There is a strong debate within the scientific community 
about the use of probiotics for the prevention of 
necrotizing enterocolitis (NEC). Several studies have 
reported that probiotics reduce the incidence of NEC 
and NEC-associated mortality in preterm infants 
and several meta-analysis have confirmed these 
results[79,80]. However, a rigorous phase 3 RCT recently 
showed no effect of B. breve BBG­001 on NEC[81]. 
Several guidelines and position papers reported that 
although a substantial body of evidence supports the 
use of probiotics, there is insufficient evidence for a 
strong recommendation nor is there consensus on 
specific strain[36]. 
The expert panel agreed that probiotics may 
be considered for the prevention of NEC as there 
is evidence that the risk of NEC and the associated 
mortality may be reduced in high-risk populations. 
However, since there is no conclusive agreement on 
whether to administer probiotics, the decisions should 
be taken in agreement with the parents, in light of 
current evidence and the benefits expected.
A summary of all recommendations for the use of 
probiotics in children is shown in Table 2.
DISCUSSION
Clinical practice guidelines are important tools for 
translating the evidence available into clinical best 
practice[82]. The development of guidelines for probiotics 
use is often hampered by several factors, including lack 
of characterization of probiotics, inadequate quality 
control of preparations and a paucity of high quality 
studies. Nevertheless, well defined clinical indications 
for the use of probiotics have been established, and 
more are emerging.
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Guidelines that have been developed in one country 
may not be applicable in other countries, depending 
on the prevalence and etiology of the clinical condition, 
as well as the availability or cost of recommended 
interventions and the organization of health care. 
Therefore, guidelines should generally be developed 
for individual countries or regions.
As outlined in the previous sections, the burden of 
intestinal diseases differs across geographic regions, 
particularly between countries in the Asia-Pacific region. 
These differences are due to numerous factors that 
must be taken into account when developing guidelines 
for the prevention and treatment of intestinal illnesses 
in children in the Asia-Pacific region. However, despite 
the largely socioeconomic disparities that exist between 
countries, the proposed recommendations were agreed 
upon by all participants to the panel coming from 
different countries in the Asia Pacific region, as judged 
by the Likert scale voting and provide guidance for 
physicians on the use of probiotics in specific intestinal 
diseases, thereby filling a gap that exists, as similar 
documents are available for other major regions of the 
world.
Factors that must be taken into consideration in 
terms of the applicability of the Asia-Pacific guidelines 
include the availability of specific probiotic strains in 
local markets, costs, patient and physician access 
to probiotic products, and personal/cultural beliefs. 
Moreover, current regulations regarding probiotics 
are country-specific in the Asia-Pacific region, as well 
as in other countries in the world. Standardization 
of a regulatory framework for probiotics would be of 
substantial benefit in terms of furthering research into 
and the use of these agents in human medicine.
Given this complex scenario and the need for sup-
porting evidence, the recommendations are provided 
as “proposed” and their potential benefits need to be 
confirmed at the local level with well-conducted RCTs.
SUMMARY OF RECOMMENDATIONS 
FOR THE ASIA-PACIFIC REGION
While it is acknowledged that more data specific to 
the Asia-Pacific region are needed for many of the 
indications, the working group proposes the following 
recommendations for pediatric intestinal diseases 
based on available data:
Acute gastroenteritis: Administration of probiotic 
strains for which there is good quality evidence of 
efficacy should be considered in adjunct to oral rehydr-
ation therapy in children with acute gastroenteritis. 
This recommendation does not include children with 
severe malnutrition. At present, S. boulardii CNCM I-745 
and L. rhamnosus GG are the two strains for which 
there is compelling evidence of efficacy. L.reuteri DSM 
17938 may be considered albeit proof of efficacy is less 
consistent.
Antibiotic-associated diarrhea: Upon evaluation 
of local conditions and risk factors, probiotics admini-
stration may be considered on a case by case basis for 
the prevention of AAD. S. boulardii CNCM I-745 and L. 
rhamnosus GG are two strains for which the quality of 
evidence is good.
C. difficile infection: For the prevention of C. difficile-
associated diarrhea, probiotics may be considered 
based on evaluation of individual cases. At present, 
the recommended strain is S. boulardii CNCM I-745 for 
which the quality of evidence is low.
Prevention of nosocomial diarrhea: Upon evalu-
ation of local conditions and risk factors, probiotics 
Table 2  Proposed recommendations for the Asia-Pacific region with grade and strength of recommendations
Disease Recommendation Strains Grade Weak
Acute gastroenteritis T Should be considered1 S. boulardii, Moderate quality Strong
L. rhamnosus GG Strong
L reuteri Weak
AAD P May be considered L. rhamnosus GG Moderate quality Strong
S. boulardii Strong
CDAD P May be considered S. boulardii Low quality Weak
Nosocomial diarrhea P Can be considered L. rhamnosus GG Moderate quality Weak
Traveler’s diarrhea P Not recommended Very low quality Weak
Functional intestinal disorders T Not recommended Very low quality Weak
Infant colics T May be considered L. reuteri Moderate quality Weak
IBD (Crohn’s disease, ulcerative colitis) T Not recommended Low quality Weak
Helicobacter pylori infection T May be considered S. boulardii, Very low quality Weak2
others Weak
Necrotizing enterocolitis Decision to be 
discussed with parents
Various (Bifidobacterium, 
Lactobacillus species)
1In adjunct to oral rehydration therapy and with the exclusion of malnourished children; 2For prevention of antibiotic-induced side effects and possible 
increase in eradication rates. T: Treatment; P: Prevention; AAD: Antibiotic-associated diarrhea; CDAD: Clostridium difficile-associated diarrhea; IBD: 
Inflammatory bowel disease. 
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may be considered to prevent hospital-acquired 
intestinal infections and diarrhea on a case by case 
basis in children admitted to hospital. Although the 
evidence remains weak, L. rhamnosus GG is the strain 
recommended for this indication.
Traveler’s diarrhea: Data on the efficacy of probiotics 
in preventing traveler’s diarrhea are insufficient to 
provide recommendations for the use of probiotics.
Functional intestinal disorders: Based on available 
data, there is insufficient evidence to recommend 
probiotics in the treatment of functional intestinal 
disorders.
Infant colic: Probiotic administration may be consi-
dered for the treatment of infantile colic. At present, 
the recommended strain is L. reuteri DSM 17938, for 
which the quality of evidence is weak.
Inflammatory bowel disease: There is no strong 
evidence supporting the treatment of IBD with probi-
otics. In pouchitis probiotic therapy may be considered 
based on evaluation of individual cases. At present, the 
recommended probiotic preparation is VSL#3 for which 
the quality of evidence is weak.
H. pylori treatment: Probiotics administration may 
be considered for the prevention of side effects and 
improving eradication rates in children undergoing 
therapy for H. pylori. The recommended strains include 
S. boulardii CNCM I-745 and others for which the 
quality of evidence is weak.
Necrotizing enterocolitis: Probiotics may be consi-
dered for prevention of NEC in high-risk populations 
as there is evidence that the risk of NEC and the 
associated mortality may be reduced. However since 
there is no agreement on strains, indications and 
scheme, the decision should be taken in agreement 
with the parents, in the light of current evidence.
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